World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience.
about
Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosisManagement of polycythaemia vera: a critical review of current data.WHO classification 2008 of myeloproliferative neoplasms: a workshop learning effect--the Danish experience.Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaMyeloproliferative neoplasms: A decade of discoveries and treatment advances.Myeloproliferative neoplasms: Morphology and clinical practice.Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.Response to Harrison et al. 'Clinically relevant differences between BCSH and WHO diagnostic criteria for ET'.Masked polycythemia vera (mPV): results of an international study.The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.Equivalence of BCSH and WHO diagnostic criteria for ET.Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis - a consensus-based study.Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes.High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.
P2860
Q26772881-180EA6E5-496D-41B6-A74F-7C2CDDD84605Q31009757-682F3B59-89DB-418C-93B0-8BA3E6EB446AQ35705470-8F2CE00E-834E-407D-9274-947CD489E109Q36874807-4DFB7206-728F-4BC9-BFBC-10B6FEA998BCQ38613880-FD3B45A5-B9F0-4A90-AA8B-4A16D5DBF37BQ38683559-3BB1E512-4F64-43D9-9CFB-81563230761DQ38706624-7E32C749-A08B-47CF-90D3-E85992A4C3DFQ38764516-5E802D01-2662-4697-BDAC-0D52685B8009Q42047635-B0378DD5-399D-405E-B866-E6A74A3EC129Q46731979-02B9A376-8D0E-4975-A899-D8CEB377DBA7Q49633536-3992B8FD-67A5-4717-AB2C-9EE50E23E00BQ50213969-07D0A781-718A-4B3F-90FA-74071D83E023Q52862082-80E7396B-27CE-4D2E-BE01-04B1BEAD4917Q52887806-F6C1AD0D-D357-480A-A7D9-8D23D049656EQ53147519-A3BBAAEE-331D-4506-BEFF-09272A68A70AQ54357496-364CB43F-347C-416C-9358-84D19D95A43B
P2860
World Health Organization-defined classification of myeloproliferative neoplasms: morphological reproducibility and clinical correlations--the Danish experience.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
World Health Organization-defi ...... ations--the Danish experience.
@en
World Health Organization-defi ...... ations--the Danish experience.
@nl
type
label
World Health Organization-defi ...... ations--the Danish experience.
@en
World Health Organization-defi ...... ations--the Danish experience.
@nl
prefLabel
World Health Organization-defi ...... ations--the Danish experience.
@en
World Health Organization-defi ...... ations--the Danish experience.
@nl
P2093
P2860
P356
P1476
World Health Organization-defi ...... ations--the Danish experience.
@en
P2093
Ann Brinch Madelung
Anne Falensteen
Elisabeth Ralfkiaer
Helle Knudsen
Henrik Bondo
Inger Stamp
Jürgen Thiele
Karsten Nielsen
Kira Dynnes Svendsen
Mats Ehinger
P2860
P304
P356
10.1002/AJH.23554
P577
2013-09-30T00:00:00Z